AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells

PURPOSE: Despite adjuvant endocrine therapy for patients with estrogen receptor alpha (ER)-positive breast cancer, dormant residual disease can persist for years and eventually cause tumor recurrence. We sought to deduce mechanisms underlying the persistence of dormant cancer cells to identify thera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Hampsch, Riley A., Wells, Jason D., Traphagen, Nicole A., McCleery, Charlotte F., Fields, Jennifer L., Shee, Kevin, Dillon, Lloye M., Pooler, Darcy B., Lewis, Lionel D., Demidenko, Eugene, Huang, Yina H., Marotti, Jonathan D., Goen, Abigail E., Kinlaw, William B., Miller, Todd W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367755/
https://ncbi.nlm.nih.gov/pubmed/32321715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0269
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados